{
    "clinical_study": {
        "@rank": "53697", 
        "acronym": "LIRA-LIXI\u2122", 
        "arm_group": [
            {
                "arm_group_label": "Metformin + liraglutide 1.8 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Metformin + lixisenatide 20 microg", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the efficacy and\n      safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2\n      diabetes (T2DM)."
        }, 
        "brief_title": "Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities. Trial-related\n             activities are any procedures that are carried out as part of the trial, including\n             activities to determine suitability for the trial\n\n          -  Subjects diagnosed with T2DM and on unchanged metformin treatment at the maximum\n             tolerated dose (at least 1000 mg/day and up to 3000 mg/day) for at least 90 days\n             prior to screening\n\n          -  HbA1c 7.5 - 10.5% (53 mmol/mol - 91 mmol/mol) (both inclusive)\n\n          -  Body Mass Index (BMI) equal to or above 20 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Female of child-bearing potential who is pregnant, breast-feeding or intend to become\n             pregnant or is not using adequate contraceptive methods. (Adequate contraceptive\n             measures as required by local law or practice)\n\n          -  Treatment with glucose lowering agent(s) other than stated in the inclusion criteria\n             in a period of 90 days prior to screening. Exception is short-term treatment (equal\n             to or below 7 days in total) with insulin in connection with intercurrent illness\n\n          -  History of chronic pancreatitis or idiopathic acute pancreatitis\n\n          -  Screening calcitonin value equal to or above 50 ng/L\n\n          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine\n             neoplasia syndrome type 2 (MEN 2)\n\n          -  Impaired liver function, defined as alanine aminotransferase (ALAT) equal to or above\n             2.5 times upper normal limit (UNL)\n\n          -  Impaired renal function defined as estimated glomerular filtration rate (eGFR) below\n             60 mL/min/1.73 m^2 per Modification of Diet in Renal Disease (MDRD) formula\n\n          -  Any episode of unstable angina, acute coronary event, cerebral stroke/transient\n             ischemic attack (TIA) or other significant cardiovascular event as judged by the\n             investigator within 90 days prior to screening\n\n          -  Heart failure, New York Heart Association (NYHA) class IV\n\n          -  Uncontrolled hypertension (defined as systolic blood pressure equal to or above 180\n             mmHg and/or diastolic blood pressure equal to or above 100 mmHg)\n\n          -  Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin\n             cancer or squamous cell skin cancer)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973231", 
            "org_study_id": "NN2211-3867", 
            "secondary_id": [
                "2012-004984-27", 
                "U1111-1136-3644"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin + liraglutide 1.8 mg", 
                "description": "Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).", 
                "intervention_name": "liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Metformin + lixisenatide 20 microg", 
                "description": "Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.", 
                "intervention_name": "lixisenatide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mlada Boleslav", 
                        "country": "Czech Republic", 
                        "zip": "293 50"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oulu", 
                        "country": "Finland", 
                        "zip": "FI-90100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lampertheim", 
                        "country": "Germany", 
                        "zip": "68623"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1042"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "zip": "90129"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia", 
                        "zip": "LV-1012"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaunas", 
                        "country": "Lithuania", 
                        "zip": "50009"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiswick", 
                        "country": "United Kingdom", 
                        "zip": "W4 3JL"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Finland", 
                "France", 
                "Germany", 
                "Hungary", 
                "Italy", 
                "Latvia", 
                "Lithuania", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "Finland: Finnish Medicines Agency", 
                "France: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Italy: Ministry of Health", 
                "Latvia: State Agency of Medicines", 
                "Lithuania: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in glycosylated haemoglobin (HbA1c) from baseline", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973231"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in fasting plasma glucose (FPG) from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Change in body weight from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Subjects who achieve HbA1c below 7.0% (53 mmol/mol) (American Diabetes Association (ADA) target) (yes/no)", 
                "safety_issue": "No", 
                "time_frame": "After 26 weeks of treatment"
            }, 
            {
                "measure": "Subjects who achieve HbA1c equal to or below 6.5% (48 mmol/mol) ((American Association of Clinical Endocrinologists (AACE) target) (yes/no)", 
                "safety_issue": "No", 
                "time_frame": "After 26 weeks of treatment"
            }, 
            {
                "measure": "Subjects who achieve HbA1c below 7.0% (53 mmol/mol) and no weight gain (yes/no)", 
                "safety_issue": "No", 
                "time_frame": "After 26 weeks of treatment"
            }, 
            {
                "measure": "Number of treatment emergent adverse events (TEAEs)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}